Current Report Filing (8-k)
April 24 2018 - 7:29AM
Edgar (US Regulatory)
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the
Securities Exchange Act of 1934
Date of Report (Date of earliest event reported):
April 24, 2018
ADMA
BIOLOGICS, INC.
|
(Exact name of registrant as specified in its charter)
|
|
|
|
Delaware
|
001-36728
|
56-2590442
|
(State or other jurisdiction
of incorporation)
|
(Commission
File Number)
|
(IRS Employer
Identification No.)
|
|
|
|
|
|
465 State Route 17, Ramsey, New Jersey
|
07446
|
(Address of principal executive offices)
|
(Zip Code)
|
Registrant’s telephone number, including
area code:
(201) 478-5552
|
(Former name or former address, if changed since last report.)
|
Check the appropriate box below if the Form 8-K filing is intended
to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (
see
General Instruction
A.2. below):
o
Written
communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
¨
Soliciting
material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
¨
Pre-commencement
communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
¨
Pre-commencement
communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Indicate by check mark whether the registrant
is an emerging growth company as defined in as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter)
or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging
growth company
ý
If
an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for
complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.
¨
On April 24, 2018, ADMA Biologics, Inc. issued a press release
announcing that it has successfully completed the manufacturing and release, and has made commercial sales, of its first batch
of Nabi-HB® (Hepatitis B Immune Globulin, Human) produced under its leadership.
The full text of the press release is filed as Exhibit 99.1
to this Current Report on Form 8-K.
|
Item 9.01
|
Financial Statements and Exhibits
.
|
(d) Exhibits
SIGNATURE
Pursuant to the requirements
of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned
hereunto duly authorized.
April 24, 2018
|
ADMA Biologics, Inc.
|
|
|
|
|
|
By:
|
/s/ Brian Lenz
|
|
|
Name:
|
Brian Lenz
|
|
|
Title:
|
Vice President and Chief Financial Officer
|
Adma Biologics (NASDAQ:ADMA)
Historical Stock Chart
From Mar 2024 to Apr 2024
Adma Biologics (NASDAQ:ADMA)
Historical Stock Chart
From Apr 2023 to Apr 2024